New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $17 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions since its founding in 1977. In the U.S., NEA has offices in Menlo Park, CA; Boston, MA; New York, NY; Chicago, IL; and the Washington, D.C. metropolitan area. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For additional information, visit www.nea.com
Since 1987, Canaan has partnered with entrepreneurs to catalyze the growth of disruptive technology startups and healthcare companies revolutionizing the practice of medicine. The firm targets early-stage investments across a wide range of sectors including financial technology, marketplaces and enterprise software, as well as biopharma, oncology and digital health. With $4.2 billion under management and over 180 exits to-date, Canaan was the first and lead investor in Lending Club (NYSE: LC), the fourth largest internet IPO in the U.S., and realized nine healthcare M&As and three IPOs since 2014. The firm has funded technology companies such as eBates (acquired by Rakuten, Inc.), Metacloud (acquired by Cisco), Skybox Imaging (acquired by Google), SuccessFactors (acquired by SAP), Tremor Video (NYSE: TRMR) and Virsto Software (acquired by VMWare), as well as notable healthcare companies such as CytomX Therapeutics (NASDAQ: CTMX), Dermira (NASDAQ: DERM), Labrys Biologics (acquired by Teva Pharmaceutical), Novira Therapeutics (acquired by Johnson & Johnson), Spinifex Pharmaceuticals (acquired by Novartis) and Transcend Medical (acquired by Alcon). Canaan maintains a presence in the global innovation hubs of Silicon Valley, New York and Connecticut, as well as a subsidiary in Israel. For more information, visit www.canaan.com and follow us on Twitter @CanaanPartners.
In June 2012, GlaxoSmithKline (GSK) made an equity investment in Liquidia as part of its option agreement to research and develop certain inhaled therapies using Liquidia’s PRINT technology and, in September 2015, GSK exercised this option to exclusively license the right to research, develop, and commercialize Liquidia’s PRINT technology in inhaled therapeutics.
Morningside Group invests in private equity and venture capital opportunities in North America, Europe and Asia Pacific. Morningside Group has investments in the following sectors: machinery manufacturing, high-tech, media, telecommunication, life science, education and cleantech. The group is managed by experienced investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside Group is deeply committed to being socially responsible. Providing access to educational opportunities and supporting scientific research are two major areas of focus for Morningside’s philanthropic endeavors. For additional information, visit www.morningside.com.
Founded in 1994, Pappas Ventures has more than $350 million in capital under management. Pappas Ventures has guided the launch and/or development of some 40 life sciences companies, a quarter of which have completed initial public offerings or successfully merged with corporate partners. Scientific, medical and business professionals on the Pappas team work closely with exceptional entrepreneurs to provide portfolio companies with the financing, guidance and extensive network of relationships necessary to build successful enterprises. Pappas Ventures is based in Research Triangle Park, NC. For additional information, visit www.pappasventures.com
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people-especially those with the fewest resources-have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett. For additional information, visit www.gatesfoundation.org.
Wakefield Group is a venture capital firm focused on providing growth capital to growing businesses. The firm focuses its investments in technology, health, and business services and media. Within healthcare the firm focuses on software, devices, and human-genome technologies. Wakefield Group was founded in 1988 and has offices in Charlotte and Chapel Hill, North Carolina.
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For additional information, visit www.ppdi.com.
Xeraya Capital is a Malaysian based Venture Capital/Private Equity investor with a primary focus on life sciences. Its priority areas are medical technologies, healthcare biotech, healthcare services, healthcare IT, bio-renewables and bio-industrials. It invests globally and currently has investments in the U.S., Europe and South-East Asia. It is a wholly owned subsidiary of Khazanah Nasional Berhad, the Malaysian Government’s strategic investment fund. For additional information, visit www.xeraya.com.